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Introduction: Apolipoprotein A1 (apoA1) is the major apoprotein constituent of high density lipoprotein (HDL)
which exerts innate protective effects in systemic inflammation. However, its role in the acute lung injury (ALI) or
acute respiratory distress syndrome (ARDS) has not been well studied. The objective of this study was to investigate
the potential association between APOA1 -75 G/A polymorphism and the development of ALI after cardiopulmonary
bypass (CPB) surgery.
Materials and methods: A hospital-based case–control study was conducted in patients with ALI (n = 300),
patients without ALI (n = 300) and healthy controls (n = 300). Polymerase chain reaction restriction fragment length
polymorphism (PCR-RFLP) assay was applied to assess the APOA1 -75 G/A genotypes.
Results: Patients with ALI had a significantly higher frequency of APOA1 -75 AA genotype [odds ratio (OR) =1.75, 95%
confidence interval (CI) = 1.04, 2.92; P = 0.03] than patients without ALI. APOA1 -75 AA genotype (OR =3.47,
95% CI = 1.60, 7.52; P = 0.002) and A allele (OR =1.92, 95% CI = 1.24, 2.96; P = 0.003) were the significant
independent prognostic factors for the 30-day survival rate of patients with ALI after CPB surgery.
Conclusion: Our study suggested that APOA1 -75 AA genotype was associated with a higher ALI risk after CPB surgery.
Patients with the APOA1 -75 AA genotype and A allele had higher 30-day mortality of ALI after CPB surgery. Additional
studies are needed to confirm this finding.
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Acute lung injury (ALI) is a common complication after
cardiopulmonary bypass (CPB) surgery. ALI remains the
main cause of mortality after CPB surgery [1]. The main
causes of ALI after CPB surgery have been identified, in-
cluding ischemia reperfusion injury, endotoxemia, primary
pulmonary disease, surgical injury, and the systemic in-
flammatory reaction initiated by the contact of the blood
leukocytes with the artificial surface of the bypass circuit
[2-5]. Improved understanding of disease heterogeneity
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stated.approaches should provide major new insights into patho-
genesis of ALI [6].
Apolipoprotein A1 (apoA1) is the major apoprotein
constituent of high density lipoprotein (HDL) which ex-
erts innate protective effects in systemic inflammation [7].
However, its role in the acute lung injury (ALI) or acute
respiratory distress syndrome (ARDS) has not been well
studied. One variant resides in the APOA1 gene, which in-
volves a guanine to adenine transition 75 base pairs (bp)
upstream from the start of transcription (G–75A) and
destroys a site for the MspI restriction enzyme. A strong
association was found between the G to A substitution
at −75 bp with serum HDL and apoA1 levels [8]. The ob-
jective of this study was to investigate the potential asso-
ciation between APOA1 -75 G/A polymorphism and theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical data of patients with or without ALI after
CPB surgery
Variable ALI Without ALI P
Total no. 300 300
Age (years) 59.1 ± 10.6 56.8 ± 9.4 0.005
Gender (Male/Female) 205/95 201/99 0.73
ASA 2.77 ± 0.71 2.67 ± 0.65 0.07
NYHA 2.69 ± 0.67 2.57 ± 0.55 0.02
LVEF (%) 59.68 ± 7.94 60.68 ± 8.04 0.13
Previous cardiac surgery (%) 45 (15.0) 30 (10.0) 0.07
Hypertension (%) 75 (25.0) 70 (23.3) 0.63
Diabetes mellitus (%) 26 (8.7) 24 (8.0) 0.77
Obesity (%) 70 (23.3) 48 (16.0) 0.03
Peripheral vascular disease (%) 43 (14.3) 26 (8.7) 0.03
Transfusion (mL) 694.3 ± 103.7 687.3 ± 99.8 0.40
Duration of operation (min) 231.7 ± 90.1 210.5 ± 82.3 0.003
Duration of CPB (min) 106.7 ± 43.7 99.5 ± 41.5 0.04
Duration of cross-clamp (min) 62.1 ± 32.4 60.7 ± 31.9 0.59
Surgery
Valvular surgery (%) 176 (58.7) 183 (61.0) 0.56
CABG surgery (%) 99 (33.0) 102 (34.0) 0.80
Aortic surgery (%) 25 (8.3) 15 (5.0) 0.11
ALI, Acute lung injury; CPB, Cardiopulmonary bypass; ASA, American Society of
Anesthesiology; NYHA, New York Heart Association; LVEF, Left ventricular
ejection fraction; CABG, Coronary artery bypass graft.
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From January 2008 to January 2013, a hospital-based
case–control study was conducted in patients with ALI
(n = 300), patients without ALI (n = 300) after CPB sur-
gery and healthy controls (n = 300) in the Institute of
cardiovascular Diseases of the First Affiliated Hospital of
Guangxi Medical University. All subjects were collected
from the same geographic region. Surgery type included
valvular surgery, coronary artery bypass graft (CABG)
and aortic surgery. The healthy control subjects were
matched with the patients for age and sex. Healthy con-
trol subjects were recruited from the First Affiliated
Hospital of Guangxi Medical University where they were
attending a clinic for routine examination. Patients who
met diagnostic criteria of acute lung injury at 24 hours
after surgery were allocated to ALI group; those without
ALI were allocated to without ALI group. ALI was de-
fined as PaO2/FiO2 < 300 mm Hg; and bilateral pulmon-
ary infiltrates on chest radiograph in the absence of
acute pulmonary edema after left cardiac failure or other
nonlung pathology 24 hours after surgery, and a left
atrial pressure lower than 18 mm Hg [9]. Patients were
excluded if they met the following criteria: immunodefi-
ciency, autoimmune disease, or immunosuppressive ther-
apy; tuberculosis, chronic obstructive pulmonary disease
(COPD), or other chronic pulmonary diseases; liver dys-
function or chronic renal disease; bleeding disorders;
anemia; postoperative pericardial tamponade requiring re-
operation; postoperative low cardiac output syndrome, or
acute pulmonary edema after left cardiac failure. The Eth-
ical Committee of the First Affiliated Hospital of Guangxi
Medical University approved the study protocols, and all
participants gave written informed consent according to
the Declaration of Helsinki.
DNA extraction and genotyping
The commercially available Qiagen kit (QIAGEN Inc.,
Valencia, CA, USA) was used to extract DNA from periph-
eral blood leukocytes. The APOA1 -75 G/A genotypes
were analyzed by polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) assay. Based
on the GenBank reference sequence, the PCR primers
were as follows: forward-5′- AGGGACAGAGCTGAT
CC-TTGAACTCTTAG -3′ and reverse-5′- TTAGGG
GACACCTACCCGTACAGGAAGAGCA -3′. DNA was
denaturanted at 94°C for 5 minutes, followed by 35 cycles
of denaturation at 94°C for 1 minute, annealing at 60°C
for 0.5 minute, and extension at 72°C for 0.5 minutes,
with a final extension step of 5 minutes at 72°C. A total
volume of 10 μl containing 20 U MspI was added directlyto the PCR product and digested at 37°C overnight. After
electrophoresis, the digested products were visualized on
a 9% polyacrylamide gel with ethidium bromide staining.
Statistical analysis
We used Statistical Analysis System software (Version 8;
SAS Institute Inc., Cary, NC, USA) to perform all of the
statistical analyses. The x2 test was used to test for devi-
ation of genotype frequencies from Hardy-Weinberg equi-
librium and to compare the genotype distributions among
patients with ALI, patients without ALI and healthy con-
trols. We applied multivariate logistic regression to cal-
culate crude and adjusted odds ratios (OR) and 95%
confidence intervals (CI) for the association between the
genotypes and the development of ALI after CPB surgery.
A P-value was considered significant at a level of < 0.05.
Results
Clinical data of patients with or without ALI after CPB
surgery were listed in Table 1. Univariate study was per-
formed to identify that age (P = 0.005), NYHA (P = 0.02),
obesity (P = 0.03), peripheral vascular disease (P = 0.03),
duration of operation (P = 0.003), and duration of CPB
(P = 0.04) were associated with ALI after CPB surgery
(Table 1). In addition, no significant differences were
Table 3 Effect of apolipoprotein A1 -75 G/A polymorphism






OR (95% CI) P value
Genotype
GG 18(36.0) 114(45.6) 1.00(Reference)
GA 15(30.0) 105(42.0) 0.91(0.43,1.89) 0.79
AA 17(34.0) 31(12.4) 3.47(1.60,7.52) 0.002
Allele
G 51(51.0) 333(66.6) 1.00(Reference)
A 49(49.0) 167(33.4) 1.92(1.24,2.96) 0.003
ALI, Acute lung injury; CPB, Cardiopulmonary bypass; OR, Odds ratio;
CI, Confidence interval.
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surgery in gender, ASA, LVEF, previous cardiac surgery,
hypertension, diabetes mellitus, transfusion, duration of
cross-clamp, and surgery type (Table 1).
Patients with ALI had a significantly higher frequency
of APOA1 -75 AA genotype (OR =1.75, 95% CI = 1.04,
2.92; P = 0.03) than patients without ALI (Table 2).
APOA1 -75 AA genotype (OR =3.47, 95% CI = 1.60,
7.52; P = 0.002) and A allele (OR =1.92, 95% CI = 1.24,
2.96; P = 0.003) were the significant independent prog-
nostic factors for the 30-day survival rate of patients
with ALI after CPB surgery (Table 3).
Discussion
Some studies have been performed to find an association
of genetic polymorphism and ALI [10]. A prospective
case–control study found that -607C/C genotype in IL-
18 gene played a pivotal role in the development of ALI
after CPB surgery in Chinese Han population [11]. An-
other case–control study found that the IL-6 -572 poly-
morphism was associated with ALI after CPB surgery [12].
Several studies have suggested that pre-B-cell colony-
enhancing factor (PBEF) gene polymorphisms were associ-
ated with susceptibility to and prognosis of ALI [13,14].
The plasminogen activator inhibitor-1 (PAI-1) 4G allele
was associated with worse outcome in ALI/ARDS [15]. A
prospective cohort demonstrated that the AC genotype at
position −1221 in the NQO1 gene caused decreased tran-
scription and was associated with a lower incidence of ALI
following major trauma [16]. In a nested case–control
study, patients with the NRF2 -617 A allele had a signifi-
cantly higher risk for developing ALI after major trauma
[17]. A case–control study found that myosin light chain
kinase (MYLK) genetic variants were associated with in-
creased risk of sepsis-associated ALI [18].
The APOA1 -75 G/A polymorphism has recently been
linked to many other diseases. A comparative study
found that carrying the APOA1 -75 A allele could
confer a higher risk of hyperlipidemia in obese childrenTable 2 Genotype and allele frequencies of apolipoprotein A1







ALI vs without A
OR (95% CI) P v
Genotype
GG 132(44.0) 144(48.0) 138(46.0) 1.00(Reference)
GA 120(40.0) 126(42.0) 129(43.0) 1.04(0.74,1.47) 0
AA 48(16.0) 30(10.0) 33(11.0) 1.75(1.04,2.92) 0
Allele
G 384(64.0) 414(69.0) 405(67.5) 1.00(Reference)
A 216(36.0) 186(31.0) 195(32.5) 1.25(0.99,1.59) 0
ALI, Acute lung injury; CPB, Cardiopulmonary bypass; vs, versus; OR, Odds ratio; CI, C[19]. A prospective case–control study found that the
APOA1 -75 G/A polymorphism influenced cholesterol
metabolism [20]. A study in healthy Tamilian volunteers
of south India found that the APOA1 -75 G/A poly-
morphism was significantly associated with HDL-C levels
[21]. A study found the APOA1 -75 G/A polymorphism
was significantly associated with plasma triglyceride levels
in men with coronary artery disease from the REGRESS
study [22]. A case–control study found the APOA1 -75G/
A promoter polymorphism was associated with variations
in serum triglyceride concentrations in hypercholesterol-
emic individuals [23]. A case–control study suggested that
a positive association was found between the APOA1 -75
A allele carriers and breast cancer risk [24]. A pilot
study in a north Indian population suggested that the
APOA1 -75 G allele might be susceptibility alleles for
myocardial infarction [25]. A case–control study found an
association of the APOA1 -75G/A promoter polymorph-
ism with cognitive performance in multiple sclerosis [26].
A cohort study found that the APOA1 -75 G allele showed
significant association with hypertension [27]. A case–
control study found the APOA1 -75 G/A polymorphism
was associated with gallstone disease [28]. A case–control-75 G/A polymorphism among patients with or without
LI ALI vs healthy controls Without ALI vs healthy controls
alue OR (95% CI) P value OR (95% CI) P value
1.00(Reference) 1.00(Reference)
.83 0.97(0.69,1.37) 0.87 0.94(0.67,1.31) 0.70
.03 1.52(0.92,2.52) 0.10 0.87(0.50,1.51) 0.62
1.00(Reference) 1.00(Reference)
.07 1.17(0.92,1.48) 0.20 0.93(0.73,1.19) 0.58
onfidence interval.
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an increased risk for Alzheimer’s disease [29]. A case–
control study found the APOA1 -75 G/A polymorphism
was significantly associated with lipid levels and coron-
ary atherosclerosis disease [30].
Some limitations of this study should be noted. First
of all, these results should be interpreted with caution
because the population was only from China, which re-
duces the possibility of confounding from ethnicity, so it
does not permit extrapolation of the results to other eth-
nic groups. Second, the sample size of this study is rela-
tively small, which may not have enough statistical power
to explore the real association. Third, this is a hospital
based case control study, so the selection bias cannot be
avoidable and the subjects may not be representative of
the general population.
In conclusion, our study suggested that APOA1 -75
AA genotype was associated with a higher ALI risk after
CPB surgery. Patients with the APOA1 -75 AA genotype
and A allele had higher 30-day mortality of ALI after
CPB surgery. Additional studies are needed to confirm
this finding.
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